Azathioprine in Dogs — and Why It Is Contraindicated in Cats

Bottom line

Azathioprine is a purine-antagonist immunosuppressant with a genuinely useful, steroid-sparing role in dogs — but it is effectively contraindicated in cats and should not be reached for in feline immune-mediated disease. Cats have very low erythrocyte thiopurine methyltransferase (TPMT) activity — on the order of 2.4–2.8 U/mL RBC versus roughly 18 U/mL in dogs — so they shunt far more of the drug down the cytotoxic pathway and develop severe, frequently fatal myelosuppression at doses dogs tolerate [1][2]. When a thiopurine-class effect is wanted in a cat, use chlorambucil instead. In dogs, azathioprine is dosed at 2 mg/kg (or 50 mg/m²) PO q24h as an adjunct to glucocorticoids, has a delayed onset of weeks, and demands serial CBC and liver-enzyme monitoring for the life of therapy [3].

Drug facts

• Class / mechanism: Thiopurine antimetabolite and prodrug. Azathioprine is converted to 6-mercaptopurine, which is then metabolized along three competing routes — to inactive thiouric acid (xanthine oxidase), to inactive methylated metabolites (TPMT), or to cytotoxic 6-thioguanine nucleotides incorporated into DNA/RNA. Those thioguanine nucleotides act as purine antagonists, preferentially anti-proliferative against dividing lymphocytes and blunting cell-mediated immunity [1].
• Canine dose: 2 mg/kg or 50 mg/m² PO q24h with food; after 2–3 weeks the interval is typically extended to every other day for maintenance. Onset of the immunosuppressive effect is delayed by weeks, so it is not a rescue drug for acute crises [3].
• Canine indications (steroid-sparing adjunct): immune-mediated hemolytic anemia (IMHA), immune-mediated polyarthritis, inflammatory bowel disease, and other immune-mediated conditions where the goal is a lower maintenance glucocorticoid dose or a faster steroid taper while holding remission [3].
• Feline status — contraindicated: cats have profoundly low TPMT activity and predictably develop severe, often irreversible leukopenia and thrombocytopenia; it is not an appropriate feline immunosuppressant [1][2].

Canine indications and efficacy

In dogs, azathioprine is used almost entirely as a second immunosuppressive agent layered onto prednisone/prednisolone rather than as monotherapy. The rationale is steroid-sparing: co-administration aims to permit a lower maintenance corticosteroid dose, or a faster taper, without losing disease control.

The evidence is genuinely mixed and should not be overstated. In idiopathic IMHA, a retrospective cohort found no survival advantage from adding azathioprine to prednisolone — one-year survival was 64% with prednisolone alone versus 69% with the combination, a non-significant difference — so the authors concluded it should be reserved for dogs with an inadequate response to glucocorticoids after 2–3 weeks rather than given reflexively [4]. Consistent with this, the ACVIM consensus statement on canine IMHA treatment positions a second agent such as azathioprine as reasonable when disease is severe or poorly responsive, while noting the underlying studies are limited and confounded by case-selection bias [3]. The pragmatic read: it earns its place in refractory or steroid-intolerant dogs, not as an automatic add-on.

Why it is contraindicated in cats: the TPMT problem

The feline contraindication is not a dosing nuance — it is a species-level metabolic defect. TPMT is one of the detoxifying branches that keep 6-mercaptopurine from accumulating as cytotoxic thioguanine nucleotides. When TPMT activity is low, proportionately more drug is shunted into the cytotoxic pathway, thioguanine nucleotides build up in the bone marrow, and profound myelosuppression follows.

Cats sit at the dangerous end of that spectrum. Erythrocyte TPMT activity in cats averages about 2.4 ± 0.4 U/mL RBC, far below the human reference range and well below dogs [1]. A parallel cross-species study measured mean TPMT of 17.9 U/mL in dogs versus 2.76 U/mL in cats (and 2.19 U/mL in horses), and the authors linked the low feline value directly to the recognized lower tolerance of cats for azathioprine [2]. Clinically this manifests as severe, sometimes non-regenerative leukopenia and thrombocytopenia that can be fatal, at doses dogs handle without incident. Dogs also show a wide inter-individual TPMT range, so a subset are relatively TPMT-deficient and at elevated myelotoxicity risk — an argument for diligent monitoring, not for feline use [2]. For any cat, the answer is a different drug.

Monitoring for myelotoxicity and hepatotoxicity

Azathioprine's two dose-limiting toxicities are bone-marrow suppression and hepatotoxicity, both managed by serial laboratory surveillance rather than clinical signs alone.

• CBC: Check a complete blood count with platelets at baseline, then every 1–2 weeks early in therapy, extending as the patient stabilizes. Myelosuppression is typically dose-dependent and reversible on withdrawal, but it can be delayed, appearing months into treatment, so monitoring cannot lapse once a dog is stable [3]. Falling neutrophils, thrombocytopenia, or a dropping PCV (awkward when the treated disease is itself IMHA) should prompt dose reduction or discontinuation.
• Liver enzymes: Monitor ALT/ALP; hepatotoxicity most often emerges in the first few weeks and usually reverses with drug withdrawal [3]. A significant enzyme rise warrants stopping the drug and reassessing.

Adverse effects and drug interactions

Beyond myelosuppression and hepatotoxicity, azathioprine can cause gastrointestinal upset (vomiting, diarrhea, anorexia) and, less commonly, pancreatitis; giving it with food mitigates GI signs. As a broad immunosuppressant it raises infection susceptibility, so intercurrent illness should be worked up promptly.

The interaction that most commonly causes harm involves allopurinol. Allopurinol inhibits xanthine oxidase — a clearance route for 6-mercaptopurine — so co-administration forces more drug down the cytotoxic pathway and can precipitate severe myelosuppression. Avoid the combination; if unavoidable, cut the thiopurine dose substantially and watch the CBC closely. Additive marrow suppression is also expected with other myelosuppressive or immunosuppressive drugs, and live vaccines are generally avoided during therapy.

Alternatives, including chlorambucil in cats

For cats, chlorambucil is the standard thiopurine-sparing choice. It is an alkylating agent that impairs DNA synthesis in rapidly dividing cells, is comparatively well tolerated in cats, and is the go-to immunosuppressant for feline inflammatory bowel disease and related immune-mediated conditions where a dog might receive azathioprine [5]. In feline IBD it is used in place of azathioprine, typically alongside a glucocorticoid such as prednisolone; the small (2 mg) tablet size aids dosing. It is not toxicity-free — it too causes marrow suppression and can affect the liver, so CBC and liver-enzyme monitoring remain mandatory — but it lacks the catastrophic TPMT-driven myelotoxicity that makes azathioprine unsafe in cats [5].

Other steroid-sparing options across both species include mycophenolate, cyclosporine (a calcineurin inhibitor useful in several immune-mediated diseases and well characterized in atopic dermatitis), and leflunomide; choice is dictated by disease, species, cost, and monitoring feasibility. The principle is simple: in dogs azathioprine is a reasonable, closely monitored steroid-sparing agent; in cats it is replaced — chlorambucil first among the alternatives.

Frequently Asked Questions

Why is azathioprine contraindicated in cats?

Cats have very low thiopurine methyltransferase (TPMT) activity — around 2.4–2.8 U/mL RBC compared with roughly 18 U/mL in dogs. TPMT is a key detoxifying pathway for the active metabolite 6-mercaptopurine, so cats shunt disproportionately more drug into cytotoxic thioguanine nucleotides that accumulate in the bone marrow. The result is severe, frequently fatal leukopenia and thrombocytopenia at doses dogs tolerate, which is why azathioprine is not used in cats [1][2].

What is the azathioprine dose in dogs?

The usual canine dose is 2 mg/kg or 50 mg/m² PO once daily, given with food. After 2–3 weeks the interval is commonly extended to every other day for maintenance. It is used as a steroid-sparing adjunct, not as monotherapy [3].

How long does azathioprine take to work?

Azathioprine has a delayed immunosuppressive effect that develops over weeks, so it is not a rescue drug for an acute immune-mediated crisis. Glucocorticoids provide the initial control, and azathioprine is added for its steroid-sparing benefit as the therapeutic effect builds [3].

What monitoring does azathioprine require?

Serial CBC with platelets and liver enzymes (ALT/ALP). Hepatotoxicity tends to appear in the first few weeks, whereas myelosuppression can be delayed by months, so bloodwork is checked at baseline, rechecked within the first couple of weeks, and continued at intervals for the duration of therapy [3].

Does azathioprine interact with allopurinol?

Yes, and dangerously. Allopurinol blocks xanthine oxidase, one of the clearance routes for 6-mercaptopurine, pushing more drug toward the cytotoxic pathway and precipitating severe myelosuppression. Avoid the combination; if unavoidable, cut the thiopurine dose substantially and monitor the CBC closely.

What can be used instead of azathioprine in cats?

Chlorambucil is the standard alternative. It is an alkylating agent that is comparatively well tolerated in cats and is the preferred immunosuppressant for feline inflammatory bowel disease and similar immune-mediated conditions. It still requires CBC and liver-enzyme monitoring but avoids the TPMT-driven myelotoxicity of azathioprine [5].

Is azathioprine effective for IMHA in dogs?

The evidence is mixed. A retrospective cohort found no survival benefit from adding azathioprine to prednisolone in idiopathic IMHA (one-year survival 69% vs 64% with prednisolone alone), so it is best reserved for dogs with an inadequate response to glucocorticoids or with severe disease rather than given to every case [3][4].

Can azathioprine be stopped abruptly?

Azathioprine itself is usually tapered rather than stopped abruptly as part of a gradual withdrawal of immunosuppression once remission is durable, but it should be discontinued promptly if significant myelosuppression or hepatotoxicity develops. Any taper is coordinated with the concurrent glucocorticoid wean.